Why Jim Cramer Would Sell Allergan (AGN) Stock on Valeant (VRX) Deal

NEW YORK (TheStreet) -- TheStreet's Jim Cramer says Herb Greenberg knows Valeant Pharmaceuticals  (VRX) better than anyone, and he has convinced Cramer that the Canadian company's problem is it must make deal after deal to keep its roll up going.

Cramer says it is interesting to see Allergan  (AGN) drop substantially for the first time, which tells him that the deal with Valeant may not be cut and dried yet. Valeant's sale of the rights some of the key drugs it acquired in its takeover of Medicis Pharmaceuticals to Nestle all hinge on this deal with Allergan. He reminds investors that Valeant only bought Medicis a few years ago.

Cramer says he is intrigued enough to sell Allergan.

AGN Price Chart

AGN Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)